There is a simple explanation for most of the mergers and acquisitions in the pharmaceutical world these days: the so-called Patent Cliff. Simply put, many of the drug industry's biggest earners - blockbuster medications that have paid the bills for the last decade - are about to lose their patent protections." Though patent losses will benefit consumers and insurers by making generic drugs more accessible, they will "mean big pharmaceutical companies are looking at gaping holes in their portfolios.
Monday, November 15, 2010
Drug Industry: Pharmaceutical Companies Find Ways To Cope As Patents Expire; FDA Criticized For Consulting Contracts
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment